animation video gallery clinical press sales
  • Elekta’s Versa HD rapidly enters service as ideal system for stereotactic radiotherapy to treat cancer patients

    CRAWLEY, England, March 13 /PRNewswire/ – A little over a year after Elekta launched its Versa HD™ radiation therapy system, this groundbreaking linear accelerator is routinely being used in the delivery of stereotactic body radiotherapy (SBRT) and radiosurgery (SRS) programs worldwide, often using volumetric modulated arc therapy (VMAT). The company reports that many Versa HD systems operating clinically are actively engaged in SBRT and/or SRS programs.

  • German clinic’s new Elekta Versa HD system boosts radiotherapy speed and precision in first patient treatments

    GELSENKIRCHEN, Germany, Dec. 26 – On October 28, clinicians at Evangelische Kliniken Gelsenkirchen (Gelsenkirchen, Germany) launched a new era of radiation therapy speed and accuracy with their first Versa HD™ case, a 72-year-old female patient with advanced (metastatic) cancer. Because the patient had received her first few fractions on the clinic’s existing linear accelerator, Evangelische Kliniken doctors were able to verify that her Versa HD treatments were faster and more accurate, and provided more protection to surrounding healthy organs.

  • Private Hospital Group in Spain Expands Radiotherapy Capabilities with Country’s First Elekta Versa HD System

    MADRID, October 21 /PRNewswire/ – HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta’s Versa HD™ system in 2015. Versa HD, to be sited in the group’s sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body. The most sophisticated linear accelerator on the market, Elekta’s Versa HD is a single system capable of delivering conventional therapies for an expansive range of indications commonly seen in the clinic, while also permitting treatment of complex cancers that require exceptional targeting accuracy.

  • Johns Hopkins Kimmel Cancer Center Acquires Elekta Versa HD System

    BALTIMORE, Sept. 10 /PRNewswire/ – The Johns Hopkins Department of Radiation Oncology and Molecular Radiation Sciences in the Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital (Baltimore, Maryland) has acquired Elekta’s Versa HD™ linear accelerator.

  • Elekta’s Versa HD System Now Features Automated Breath Hold Gating for Improved Breast and Lung Radiotherapy

    CRAWLEY, England, Aug. 21 – Users of Elekta’s groundbreaking linear accelerator, Versa HD™, can now bring target immobilization to new levels through automated gating with Active Breathing Coordinator™. For anatomies affected by respiratory motion, such as lung, liver and breast, Active Breathing Coordinator provides non-invasive, internal immobilization of the target, triggering radiation delivery when anatomy is immobilized.

  • Denmark’s Odense University Hospital Delivers Cancer Patients’ Stereotactic Radiation Therapy Nearly Three Times Faster with Elekta’s Versa HD System

    ODENSE, Denmark, July 24 /PRNewswire/ – Thanks to Odense University Hospital’s (OUH) new Versa HD™ system from Elekta, the delivery of the third and final stereotactic radiation treatment for a 69-year-old male lung cancer patient was almost three times quicker than his first two sessions delivered on OUH’s existing radiation therapy system. The third “fraction” took 2.5 minutes to deliver the treatment versus seven minutes required on the existing linear accelerator.

  • Seattle’s Swedish Cancer Institute Acquires Four Elekta Versa HD Radiation Therapy Systems

    SEATTLE, July 3 - Swedish Cancer Institute (SCI, Seattle), a major cancer-care network in Washington state, recently announced the acquisition of four Versa HD™ systems, a sophisticated radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body. The most advanced linear accelerator on the market, Elekta’s Versa HD is a single system capable of delivering conventional therapies for an expansive range of indications commonly seen in the clinic, while also permitting treatment of complex cancers that require exceptional targeting accuracy.

  • Kettering Medical Center Acquires Elekta’s Versa HD Radiotherapy System

    KETTERING, Ohio, June 3 - Shorter waiting and treatment times on horizon for Western Ohio cancer patients

  • Leeds’ St James’s Institute of Oncology Acquires Two Elekta Versa HD Radiotherapy Systems

    LEEDS, England, May 27 – St James's Institute of Oncology, a leading radiotherapy center in the UK, recently ordered two Versa HD™ systems, an advanced linear accelerator designed to improve patient care and treat a wide range of tumors throughout the body. As the latest, most sophisticated cancer treatment system on the market, Versa HD can help maximize health care resources. The system can deliver conventional therapies to a wide range of tumors throughout the body, while also permitting treatment of complex cancers that require extreme targeting accuracy.

  • Puerto Rico’s Caribbean Imaging and Radiation Therapy Center Orders Elekta’s New Versa HD System for Treatment of Cancer Patients

    PONCE, Puerto Rico, May 17 - Serving a region of 650,000 inhabitants in southern, central and western Puerto Rico, Caribbean Imaging and Radiation Therapy (CIRT, Ponce, PR) Center has improved its radiation therapy capabilities with the acquisition of an Elekta Versa HD™ system, the first in Puerto Rico. Versa HD offers clinicians the versatility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.

  • MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems

    HOUSTON, April 18 – The University of Texas MD Anderson Cancer Center (Houston, Texas) has purchased two Elekta Versa HD™ linear accelerators. The radiation therapy system, which recently received 510(k) clearance from the U.S. Food and Drug Administration, features the versatility to deliver high-volume conventional techniques, in addition to the most advanced linear-accelerator treatments that require the greatest targeting precision. MD Anderson predicts it will be ready to treat patients on the systems by January 2014.

  • Elekta Receives U.S. FDA 510(k) Clearance Following Launch of New Versa HD Radiation Therapy System for Cancer Treatment

    STOCKHOLM, April 11 – Elekta recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to begin shipping and installation of all components of the Versa HD™ system within the United States. Featuring high precision beam shaping and tumor targeting, and capable of delivering radiation doses three times faster than previous Elekta linear accelerators, Versa HD sets a higher benchmark for cancer treatment.

  • U.K. Clinic Anticipating New Era of Radiotherapy Speed and Precision with Elekta’s New Versa HD System

    MANCHESTER, England, April 10 – Featuring a revolutionary combination of speed and accuracy, Elekta’s new Versa HD™ system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels. Christie clinicians – who expect Versa HD to benefit a wide spectrum of patients suffering from head-and-neck, prostate and lung cancers – predict the system will be ready to begin treating patients by late spring.

  • Elekta’s Advanced Versa HD System to Begin Treating Cancer Patients at New Swiss Radiotherapy Clinic

    VEVEY, Switzerland, March 27 – Cancer patients referred to Hôpital Riviera’s (Vevey, Switzerland) new radiotherapy clinic will soon benefit from the center’s acquisition of Elekta’s advanced new linear accelerator, Versa HD™. The system, currently being installed, will be the centerpiece of Hôpital Riviera’s modern radiotherapy department, which is scheduled to begin patient treatments in June. Hôpital Riviera will maintain its collaborative clinical operations with Centre Hospitalier Universitaire Vaudois (CHUV, Lausanne).

  • Denmark’s Odense University Hospital Orders Elekta’s New Versa HD Linear Accelerator for Radiotherapy Treatment of Patients with Cancer

    STOCKHOLM and ODENSE, March 14 – Odense University Hospital (OUH, Odense) recently signed an order to acquire two Versa HD™ radiation therapy treatment systems. On March 1, Elekta announced the global launch of Versa HD, an advanced linear accelerator designed to improve patient care and treat a broader range of cancers, and featuring ultra-conformal beam shaping and tumor targeting.

  • Elekta Sets New Benchmark for Cancer Treatment with Launch of Versa HD System

    ATLANTA and STOCKHOLM, March 1 – During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.